neurodegenerative diseases/triglyceride

The present invention relates to a method for treating neurodegenerative conditions, particularly those in which increase in transforming growth factor .beta. (TGF-.beta.) is beneficial, particularly TGF-.beta.1. More particularly the present invention provides treatment for conditions such as

TECHNICAL FIELD The present invention relates to a pharmaceutical composition for treating or preventing a neurodegenerative disease comprising an RXR agonist as an active ingredient. BACKGROUND ART There have been studies on a strategy for treating neurodegenerative diseases, in particular dementia

FIELD OF THE INVENTION The present invention relates to methods of prevention, treatment or alleviation of cachexia and other wasting syndromes or conditions of loss of weight and/or muscle atrophy by modulation, including inhibition, of lipase, particularly adipose triglyceride lipase (ATGL). The

DESCRIPTION This invention relates to the use of nucleic acid sequences of the MAP kinase-interacting kinase (Mnk) gene family and amino acid sequences encoded thereby, and to the use of these sequences or effectors of Mnk nucleic acids or polypeptides, particularly Mnk kinase inhibitors and